Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lipocine Inc. before investing.

In this article, we go over a few key elements for understanding Lipocine Inc.’s stock price such as:

• Lipocine Inc.’s current stock price and volume
• Why Lipocine Inc.’s stock price changed recently
• Upgrades and downgrades for LPCN from analysts
• LPCN’s stock price momentum as measured by its relative strength

About Lipocine Inc. (LPCN)

Before we jump into Lipocine Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company’s products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Want to learn more about Lipocine Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lipocine Inc..

Lipocine Inc.’s Stock Price as of Market Close

As of April 22, 2026, 11:02 AM, CST, Lipocine Inc.’s stock price was $2.345.

Lipocine Inc. is down 0.21% from its previous closing price of $2.350.

During the last market session, Lipocine Inc.’s stock traded between $2.320 and $2.370. Currently, there are approximately 5.68 million shares outstanding for Lipocine Inc..

Lipocine Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lipocine Inc. Stock Price History

Lipocine Inc.’s (LPCN) price is currently down 70.65% so far this month.

During the month of April, Lipocine Inc.’s stock price has reached a high of $9.300 and a low of $1.810.

Over the last year, Lipocine Inc. has hit prices as high as $12.370 and as low as $1.810. Year to date, Lipocine Inc.’s stock is down 70.8%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lipocine Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 21, 2026, there were analysts who downgraded Lipocine Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lipocine Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lipocine Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Lipocine Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lipocine Inc. (LPCN) by visiting AAII Stock Evaluator.

Relative Price Strength of Lipocine Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 21, 2026, Lipocine Inc. has a weighted four-quarter relative price strength of 8.97%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Lipocine Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lipocine Inc. Stock Price: Bottom Line

As of April 22, 2026, Lipocine Inc.’s stock price is $2.345, which is down 0.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lipocine Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.